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Abstract Factor VII (FVII) deficiency is the most preva-
lent rare bleeding disorder in the USA and affects
approximately 1 out of every 500,000 people. Warfarin
inhibits the synthesis of FVII, in addition to other clotting
factors. Warfarin is contraindicated in patients with
bleeding tendencies or blood dyscrasias; therefore, the lit-
erature regarding the use of warfarin in FVII deficiency is
very limited. We report a successful re-challenge of war-
farin therapy in a patient with FVII deficiency. A 70-year-
old woman with FVII deficiency experienced a significant
decrease in FVII activity and subsequent vaginal bleeding
roughly 5 weeks after starting warfarin for atrial fibrilla-
tion. The patient was switched to aspirin therapy. Nearly 4
years later, warfarin therapy was re-attempted by a dif-
ferent haematologist. After 9 months, FVII activity
remained in an acceptable range and no bleeding events
had occurred. In addition, once the maintenance dose was
established, the international normalized ratio remained
within the goal range (1.5–2.0) for the majority of assess-
ments. Regarding future considerations, we hypothesize
that anticoagulants that do not directly affect FVII, such as
the direct oral anticoagulants, would carry less risk of
bleeding complications and therefore may be safer alter-
natives to warfarin to reduce the risk of thromboembolic
stroke in patients with atrial fibrillation and FVII
deficiency.
Key Points
We observed a successful re-challenge of warfarin
therapy in a patient with atrial fibrillation and
factor VII (FVII) deficiency.
Challenges with using warfarin therapy in FVII
deficiency include lack of a defined optimal target
international normalized ratio range and a poor
correlation between the degree of FVII deficiency
and bleeding risk.
We hypothesize anticoagulants which do not directly
affect FVII, such as the direct oral anticoagulants,
may carry less risk of bleeding complications than
warfarin to reduce the risk of thromboembolic stroke
in patients with atrial fibrillation and FVII
deficiency.
Introduction
The coagulation pathway is a complex system and is an
essential part of haemostasis [1]. It involves a number of
enzymatic steps, which activate circulating clotting factors,
ultimately leading to clot formation (see Fig. 1). Coagu-
lation is typically initiated through the extrinsic pathway
when tissue injury exposes tissue factor. Circulating fac-
tor VII (FVII) binds to tissue factor, and the resulting
complex becomes activated FVII (FVIIa). FVIIa then
directly catalyses the conversion of factor X to factor Xa
(FXa) in the common pathway and indirectly via the
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activation of factor IX to factor IXa. While the extrinsic
pathway initiates haemostasis, sustained haemostasis is
dependent upon the continued and amplified procoagulant
action of the intrinsic pathway, which involves factors
VIII, IX, XI and XII [2, 3].
Given the complex nature of the coagulation pathway,
one can appreciate the complexity of coagulation disorders.
Classical bleeding disorders include haemophilia A and B;
however, a number of rare bleeding disorders (RBDs) exist
[4]. RBDs represent only about 3–5 % of inherited coag-
ulation deficiencies and include deficiencies in fibrinogen;
factors II, V, V ? VIII, VII, X and XIII; and a combina-
tion of the vitamin K-dependent factors [5]. The most
prevalent RBD is FVII deficiency, which affects approxi-
mately 1 out of every 500,000 people in the USA, and the
prevalence varies in other countries [6]. FVII deficiency is
an autosomal-recessive bleeding disorder. The hallmark of
FVII deficiency is a prolonged prothrombin time (PT) and
an elevated international normalized ratio (INR) in the
setting of normal liver function and a normal activated
partial thromboplastin time (aPTT) [7].
Managing an FVII-deficient patient presents several
challenges. First, FVII can potentially exist in several dif-
ferent forms, and measuring FVII is further complicated by
the many different assays available [8–10]. For the pur-
poses of this article, FVII is reported as FVII coagulation
activity (FVIIc), expressed as a percentage, with normal
activity being 50–150 %. Our institution utilized a one-step
clotting assay, with the result being normalized to deter-
mine the percentage activity. Second, determining disease
severity on the basis of FVIIc is also difficult, as there is a
poor correlation between FVIIc and bleeding risk, as some
patients with moderate to severe deficiency may remain
asymptomatic, while others with mild deficiency may
experience major bleeding events [11]. Disease severity
may be better classified on the basis of the location and
frequency of bleeding events [7, 12]. A recent retrospective
analysis of 83 patients with FVII deficiency undergoing
surgical procedures recommended using FVII levels, the
bleeding history and the type of surgery to help estimate
bleeding risk and guide perioperative management [13].
Lastly, gene analysis is also difficult to interpret, as there
are over 130 known mutations, with many still lacking
defined phenotypic characteristics [11]. Progress is being
made as national and international registries for RBDs
continue to provide information about FVII deficiency.
Although RBDs inherently limit coagulation and may
predispose patients to bleeding, patients with FVII defi-
ciency may still require anticoagulation therapy if indi-
cated. A case series analysed thromboembolic events in
patients with FVII deficiency and concluded that those with
mild FVII deficiency should not be precluded from
receiving antithrombotic prophylaxis [14]. Historically,
warfarin has been the initial treatment of choice in this
limited patient population. Warfarin works by blocking the
regeneration of vitamin K epoxide, thus inhibiting the
synthesis of vitamin K-dependent clotting factors II, VII,
IX and X, as well as the anticoagulant proteins C and S.
There is evidence to suggest that not all of the vitamin K-
dependent clotting factors are affected equally by warfarin,
with FVII and factor IX being suppressed to a greater
degree than factors II and X [15]. The PT is used to
monitor warfarin therapy and is converted to an INR for
standardization. The PT reflects the functionality of several
different clotting factors, including the vitamin K-depen-
dent clotting factors; however, a prolonged PT is not seen
until one of the clotting factors has decreased to\30–40 %
[16]. For conventional patients who are stable on warfarin
Fig. 1 Effects of multiple
anticoagulant medications on
the coagulation cascade
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therapy, the INR should accurately represent variations in
coagulation factor activities [17]. However, in the presence
of FVII deficiency, the INR may not as accurately represent
the degree of coagulation ability, given the inherent
decrease of FVII in this RBD. Monitoring treatment
through FVII activity may also prove to be difficult, as the
minimal levels needed to sustain haemostasis are not well
established [7]. There is limited published literature to
guide anticoagulation therapy and monitoring in this pop-
ulation due to the rare nature of the disorder.
Three case reports involving the use of vitamin K
antagonists for atrial fibrillation in patients with FVII
deficiency have been published:
• The first case was a 50-year-old male with a prolonged
PT and an INR of 1.5 at baseline [18]. He developed an
INR of 19.6 after four doses of warfarin 5 mg, which
prompted discontinuation. Two weeks later, laboratory
analysis revealed an FVIIc of 43 %, which led to the
diagnosis of mild FVII deficiency. Warfarin was re-
started at a higher INR goal of 2.5–3.5 to ensure
adequate anticoagulation in the presence of an elevated
baseline INR. After 18 months, no bleeding or throm-
botic events were reported, despite the INR being in the
therapeutic range only 32 % of the time.
• The second case was a 77-year-old female [19]. She
developed an INR of 6.0 after two doses of warfarin
10 mg, which prompted discontinuation. Thirteen days
later, her INR was 2.2. Warfarin was re-started, and
over the next few months, the patient’s INR ranged
from 2.2 to 3.8 with doses ranging from 0.5 to 4 mg
weekly. When warfarin was withheld for 2 weeks and
the patient’s INR remained elevated at 3.5, she was
evaluated for an RBD. Laboratory analysis revealed an
FVIIc of 14 %. It was concluded that the risks with
warfarin outweighed the benefits, and the patient was
switched to aspirin.
• The third case was an 80-year-old male with a baseline
INR of 2.1 and an FVIIc of 10 % [20]. His INR goal
was set at 2.5–3.0. While his INR was within the goal
range, his FVIIc decreased to 5 % (equal to a 50 %
decrease from baseline), whereas none of the other
vitamin K-dependent clotting factors decreased more
than 30 % in comparison with baseline. Given the risk
of bleeding and perceived inadequate anticoagulant
effect, warfarin was discontinued, and enoxaparin (a
low molecular weight heparin [LMWH]) was initiated,
which was monitored using anti-FXa activity. The
patient received enoxaparin for 3 months without any
bleeding symptoms before undergoing successful
cardioversion.
In summary, although none of these patients developed
major bleeding symptoms with vitamin K antagonist
therapy, all encountered challenges with monitoring and
accurate assessment of the anticoagulant effect. Such
challenges lead to uncertainties in how to implement
anticoagulation therapy in patients with this RBD, as fur-
ther highlighted by the case summary below.
Case Report
A 70-year-old African American female with atrial fibril-
lation was referred to haematology in 2010 for evaluation
of a mildly prolonged PT with persistent vaginal bleeding.
Laboratory test results revealed a decreased FVIIc of 33 %
(reference 50–150 %), and FVII deficiency was diagnosed.
The patient underwent endometrial cryotherapy, and after 4
months without recurrent vaginal bleeding, haematology
cleared the patient to start warfarin therapy, with an INR
goal of 2.0–3.0. Haematology recommended discontinuing
warfarin if FVIIc decreased to 10 % or less. The patient’s
baseline INR was 1.4, and warfarin was conservatively
started at 2 mg daily. The INR remained at 1.4 for the first
4 weeks of therapy, despite gradual dose increases. Nearly
6 weeks into therapy, the patient made a dosing error,
which caused her INR to increase to 2.5. She developed
recurrent vaginal bleeding, and her FVIIc was found to be
10 %, which prompted warfarin discontinuation. She was
switched to aspirin 81 mg daily.
In 2014, she was evaluated by a different haematologist.
Her FVIIc was 44 %, with a baseline INR of 1.2. It was
decided to re-attempt warfarin therapy with a lower INR
goal of 1.5–2.0, as the risks of stroke without anticoagu-
lation seemed to outweigh the risks of bleeding with anti-
coagulation. The patient’s risk factors for stroke had not
changed since her initial warfarin course. Haematology
recommended discontinuing warfarin if FVIIc decreased to
\15% or if the patient developed any clinical signs of
bleeding. A total weekly dose of 40 mg was found to
maintain her INR in the range of 1.6–1.8. The FVIIc varied
between 24 and 28 % during the first 6 months of warfarin
therapy. During the seventh month, the patient’s FVIIc
decreased to 15 %, with a corresponding increase in her
INR to 2.4, despite no change in her weekly dose. The
patient denied any signs of bleeding during this second
treatment course. Her weekly doses, INR results and FVIIc
results are shown in Table 1.
Discussion
Our case report describes a successful re-challenge of
warfarin therapy in a patient with FVII deficiency. How-
ever, we must recognize the varying degrees of FVIIc and
the corresponding bleeding risk among patients with FVII
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deficiency. When our case is compared with the two patient
cases that required vitamin K antagonist discontinuation,
our patient had a more mild FVII deficiency and main-
tained higher FVIIc activity during anticoagulation ther-
apy. For patients with lower FVIIc at baseline or who
experience bleeding events or significant decreases in
FVIIc with warfarin therapy, alternative therapies could be
considered.
Our patient was initially treated with warfarin in 2011.
At that time, evidence-based practice guidelines recom-
mended long-term antithrombotic therapy with either
warfarin or aspirin, since the patient had only one major
risk factor—hypertension [21, 22]. In 2014, however,
updated guidelines now favoured anticoagulation therapy
for our patient, despite no change in her risk factors
[23, 24]. The American Heart Association/American Col-
lege of Cardiology/Heart Rhythm Society (AHA/ACC/
HRS) 2014 guidelines recommend using the CHA2DS2-
VASc scoring system to assess stroke risk. The CHA2DS2-
VASc score for our patient was 3, due to hypertension,
female sex, and age C65 years. For scores C2, anticoag-
ulation therapy is recommended (warfarin: level of evi-
dence—A; dabigatran, rivaroxaban, apixaban: level of
evidence—B) [24]. These changes in treatment guidelines
are significant for our patient, as aspirin is no longer con-
sidered an acceptable treatment option on the basis of her
risk factors.
The new agents mentioned above represent a new group
of anticoagulants known as direct oral anticoagulants
(DOACs). This group currently includes direct thrombin
(factor II [FII]) inhibitors (dabigatran) and direct FXa
inhibitors (rivaroxaban, apixaban and edoxaban). The
mechanisms by which both classes of agents act target a
clotting factor only in the common pathway of the coag-
ulation cascade, independent from FVII. Laboratory
analysis has shown that these agents do not inhibit FVII
[25, 26]. In contrast, warfarin inhibits FVII in the extrinsic
pathway. Clinical studies have shown dabigatran, rivarox-
aban, apixaban and edoxaban to be comparably safe and
effective in comparison with warfarin therapy for the
treatment of atrial fibrillation, although patients with FVII
deficiency and other RBDs were excluded from the trials
[27–30]. However, because these agents provide thera-
peutic anticoagulation by targeting clotting factors below
FVII in the clotting cascade (Fig. 1) and do not directly
affect FVII activity, they may theoretically carry less
bleeding risk than warfarin in patients with FVII
deficiency.
This suggestion to choose an anticoagulant that does not
affect FVII activity is supported by the case report [20] in
2009, which emphasized heparin use in patients with FVII
deficiency. In that case, LMWH was safely tolerated
throughout the duration of maintenance therapy. However,
at that time, the DOACs were not approved or available for
use. Interestingly, the DOACs have mechanisms of action
similar to those of heparin, targeting FXa and/or FII. While
heparin remains a viable option, it must be administered
parenterally, which is a disadvantage in comparison with
orally administered medications. One important difference
between LMWH and the DOACs is the ability to monitor
the anticoagulant effect beyond the FVIIc activity assay, as
LMWH can be monitored using anti-Xa levels, which
correlate with the actual bleeding risk. This ability (not
requirement) to monitor the anticoagulant effect may serve
as an advantage in this population at higher risk of bleed-
ing, as it gives the clinician a method to objectively assess
the degree of anticoagulation being provided. The DOACs
rivaroxaban, apixaban and edoxaban are FXa inhibitors
and, although anti-Xa level monitoring is not performed
clinically, it would seem reasonable that it could be utilized
Table 1 Case patient dose, international normalized ratio (INR) and factor VII coagulation activity (FVIIc) results
Date Dose (mg/week) INR FVIIc (%) Comments
September 27, 2010 None 1.3 33 First haematology consultation
April 11, 2011 None 1.4 – Warfarin 2 mg daily started—1st attempt
May 5, 2011 24 1.4 37
May 23, 2011 56 2.5 10 Dose error, recurrent vaginal bleeding, warfarin
discontinued
March 26, 2014 None 1.2 44 Second haematology consultation
June 19, 2014 None 1.2 – Warfarin 2 mg daily started—2nd attempt
August 11, 2014 32 1.4 24
October 7, 2014 40 1.7 28
December 11, 2014 40 1.7 32
January 27, 2015 40 2.4 15 No signs/symptoms of bleeding, warfarin dose
decreased to 38 mg/week
March 3, 2015 38 1.6 30
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with these agents as well [31]. Lastly, the initial lack of
antidotes or reversal agents for the DOAC class was con-
sidered to be a disadvantage but, recently, highly specific
reversal agents have been developed and studied with
positive results in clinical trials [32, 33]. Before reversal
agents were available, a subgroup analysis from the
ROCKET-AF trial of 779 patients who experienced major
bleeding revealed no differences in outcomes in patients
treated with rivaroxaban versus warfarin, including death
(20.4 vs 26.1 %; hazard ratio 0.69, 95 % confidence
interval 0.46–1.04). There was also less use of prothrombin
complex concentrate (PCC) and significantly less use of
fresh frozen plasma (FFP) with rivaroxaban compared with
warfarin [34]. This information supports the consideration
of DOACs as a potential alternative to vitamin K antago-
nists, even in unique and high-risk patient situations.
Conclusion
Warfarin has been the treatment of choice for throm-
boembolic conditions for multiple decades, but the data are
limited in patients with RBDs. We have described a suc-
cessful re-challenge of warfarin therapy in a patient with
FVII deficiency. However, compared with our patient case,
patients with more severe FVII deficiency at baseline or
those who experience lower levels of FVII activity during
warfarin therapy may not observe the same positive
response. The emergence of the DOAC group of antico-
agulants has provided more options for clinicians when
treating patients with RBDs in the outpatient setting. Based
on their mechanisms of action in relation to the coagulation
cascade, it would seem DOACs could potentially be safer
alternatives to warfarin for patients with FVII deficiency by
providing similarly therapeutic anticoagulation with less
bleeding risk. Future studies would be helpful to evaluate
the safety and effectiveness of DOAC therapy in patients
with FVII deficiency. However, because of the rare nature
of the disorder, it is not feasible to conduct prospective,
randomized studies. Large clinical trials of anticoagulants
typically exclude patients with FVII deficiency and other
RBDs, although this would be an excellent way to obtain
more data. It is imperative for clinicians to publish case
reports and other retrospective data to guide future therapy
in this population.
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